Posted by Michael Wonder on 26 Sep 2018
FDA grants QIDP and fast track designations to Cidara Therapeutics’ rezafungin prophylaxis development program
25 September 2018 - Rezafungin designated for the prevention of invasive fungal infections in adults undergoing bone marrow transplantation.
Cidara Therapeutics today announced that the U.S. FDA has granted both Qualified Infectious Disease Product (QIDP) and fast track designations for the company’s prophylaxis development program for lead anti-fungal product candidate, rezafungin for injection.
Specifically, the QIDP designation is for the development of rezafungin for the prevention of invasive fungal infections in adults undergoing allogeneic bone marrow transplantation. Cidara previously announced QIDP designation for rezafungin for the treatment of invasive fungal infections caused by Candida.
